Cancer API Market Overview:
This MRFR report offers a comprehensive analysis on the current Cancer API Market landscape, highlighting the recent historical growth of the market and its prospects over the next five years, until 2023.
The scope of the discussion covers five major API molecules categories namely, Tinib, Rafenib, Parib, Lisib, Degib, and Ciclib. Under the Tinib category, the molecules considered are Ponatinib, Brigatinib, Ruxolitinib, Erlotinib, Alectinib, Cobimetinib, Neratinib, Osimertinib, Acalabrutinib, Bosutinib, Crizotinib, Axitinib, Sunitinib, Ceritinib, Imatinib, Lapatinib, Afatinib, Cabozantinib, Dasatinib, Ibrutinib, Lenvatinib, and Gefitinib. Under Rafenib category the molecules considered include Sorafenib, Regorafenib, Vemurafenib, Dabrafenib, and Enasidenib. Under Parib category the molecules considered are Olaparib, Rucaparib, and Niraparib. Under the Lisib category, Idelalisib and Copanlisib have been profiled. Under the Degib category, Sonidegib and Vismodegib are the two major molecules reviewed. Under the Ciclib category molecules considered are Palbociclib, Ribociclib, and Abemaciclib.
Get Exclusive Sample Copy of Cancer API Market Report spread across 110 Premium Pages, Top 10 Companies Profile and Supported with 135 Tables and Figures is Now Available @ https://www.marketresearchfuture.com/sample_request/6243 .
Cancer API molecules have been categorized into five major categories, such as Parib, Rafenib, Lisib, Degib, Tinib, and Ciclib. Under the Tinib category, the molecules included are Cobimetinib, Brigatinib, Ruxolitinib, Ponatinib, Erlotinib, Alectinib, Osimertinib, Bosutinib, Axitinib, Ceritinib, Sunitinib, Acalabrutinib, Lenvatinib, Imatinib, Neratinib, Lapatinib, Afatinib, Crizotinib, Cabozantinib, Dasatinib, Ibrutinib, and Gefitinib. In the Rafenib category, the molecules comprise of Regorafenib, Sorafenib, Dabrafenib, Vemurafenib, and Enasidenib. Under Parib category the molecules included are Rucaparib, Olaparib, and Niraparib. Under the Lisib category molecules, namely, Copanlisib and Idelalisib are considered. Under the Degib category, two major molecules are considered which are Vismodegib and Sonidegib. In the Ciclib category, molecules considered are Ribociclib, Palbociclib, and Abemaciclib.
Detailed Regional Analysis
The cancer API market varies from region to region and country to country on the basis of the approval process. All the five cancer API category molecules are recognized in the US. For instance, Brigatinib which is an oral, small molecule drug. It is well known as an Anaplastic Lymphoma Kinase (ALK) and Epidermal Growth Factor Receptor (EGFR) reversible dual inhibitor. Brigatinib had been created by Ariad Pharmaceuticals which is a subsidiary of Takeda Pharmaceutical Company Limited. The FDA had approved Brigatinib in April 2017 for the management of advanced ALK-positive metastatic non-small cell lung cancer. Takeda also has official rights for marketing this drug under the brand name “Alunbrig.” Furthermore, Neratinib which is also an oral, small molecule drug, was FDA approved in July 2017 for the treatment of HER2 breast cancer. Neratinib is also currently under investigation for use in other types of cancers, whereas in Europe and Japan the approval of molecules is in progress.
The demand for cancer API drugs in segments such as that of oncology is unprecedented. Growing demand for newly developed small molecule drugs is motivating the development of the Cancer API Market greatly due to the noteworthy developments in small molecule API manufacturing. As a result, contract manufacturers who are focused on the development and production of small-molecule APIs are witnessing significant growth. Both biopharmaceutical and small-molecule approaches have established track records for providing valuable therapeutic benefits to patients, due to their inherent advantages and disadvantages and will remain as complementary approaches for drug discovery in the market for the foreseeable future.
The pharmaceutical industry’s attention had significantly shifted away from the industry of chemistry and small molecules, to focus on monoclonal antibodies and recombinant proteins, which are highly demanded in the market. This shift had led to the migration of many CMOs to higher-value biologics manufacturing, mothballing plants or exiting the business completely thereby slowing down market growth. However, over the past few years, the attention of the pharmaceutical industry is reverting back to small molecule therapeutics increasingly. With big players exiting the business, the prospects for smaller or newer CMOs for small molecule cancer API manufacturing have improved and will increase in abundance in the global market.
Emergent worldwide demand for products, growing expansion of infrastructure in developing countries, and a couple of runaway successes launched in the market will generate more opportunities in the near future for market expansion. The reduced prices of drugs have boosted the volume consumption of the drug, as payers fund them freely, thus, increasing their accessibility. The resulting increase in API volume will create immense opportunities for API manufacturers in the cancer API market during the forecast period.
The cancer API market is a vast market with numerous major market competitors functioning in many regions of the world. These competitors have come up with advanced drugs that are being used as a first line and second line therapy in the treatment of numerous types of cancers. Pfizer Inc, Eisai Ltd, Exelixis Inc, Bristol-Myers Squibb, F. Hoffman La Roche, AstraZeneca plc, Boehringer Ingelheim, Novartis AG, Bayer AG, Celgene, Clovis Oncology, Ariad Pharmaceuticals (Takeda),Eli Lilly & Company, AbbVie Inc., Gilead Lifesciences, Incyte Corporation, Puma Biotech, and TESARO, Inc, and others.
Get Discount @ https://www.marketresearchfuture.com/check-discount/6243 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312